4//SEC Filing
Lee Yuchun 4
Accession 0001209191-23-004816
CIK 0000875320other
Filed
Jan 24, 7:00 PM ET
Accepted
Jan 25, 4:08 PM ET
Size
16.1 KB
Accession
0001209191-23-004816
Insider Transaction Report
Form 4
Lee Yuchun
Director
Transactions
- Exercise/Conversion
Common Stock
2023-01-23$72.14/sh+2,129$153,586→ 4,004 total - Exercise/Conversion
Common Stock
2023-01-24$72.14/sh+4,000$288,560→ 5,875 total - Sale
Common Stock
2023-01-24$312.29/sh−2,511$784,160→ 3,364 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-01-23−2,129→ 13,429 totalExercise: $72.14Exp: 2024-05-31→ Common Stock (2,129 underlying) - Sale
Common Stock
2023-01-23$312.02/sh−2,129$664,291→ 1,875 total - Sale
Common Stock
2023-01-24$313.36/sh−1,489$466,593→ 1,875 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-01-24−4,000→ 9,429 totalExercise: $72.14Exp: 2024-05-31→ Common Stock (4,000 underlying)
Footnotes (6)
- [F1]Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
- [F2]Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F3]Open market sales reported on this line occurred at a weighted average price of $312.02 (range $312.00 to $312.17).
- [F4]Open market sales reported on this line occurred at a weighted average price of $312.29 (range $312.00 to $312.92).
- [F5]Open market sales reported on this line occurred at a weighted average price of $313.36 (range $313.00 to $313.73).
- [F6]Fully vested.
Documents
Issuer
VERTEX PHARMACEUTICALS INC / MA
CIK 0000875320
Entity typeother
Related Parties
1- filerCIK 0001334365
Filing Metadata
- Form type
- 4
- Filed
- Jan 24, 7:00 PM ET
- Accepted
- Jan 25, 4:08 PM ET
- Size
- 16.1 KB